Man-Si Wu1, Qing-Yu Ma1, Dong-Dong Liu1, Xiao-Juan Li1, Li-Juan Deng1, Nan Li1, Jingnan Shen2, Zhiqiang Zhao3, Jia-Xu Chen4. 1. Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China. 2. Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. 3. Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. zhiq811@163.com. 4. Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China. chenjx@jnu.edu.cn.
Abstract
BACKGROUND: We investigated the microarray data GSE42352 to identify genes that can be used as prognosis factors in osteosarcoma. METHODS: Gene Ontology (GO) biological process analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of Cytoscape ClueGo were used in verifying the function of different genes. Realtime-PCR were used to confirm the microarray results. 83 patient samples were collected and underwent Kaplan-Meier survival analysis and multivariate analysis to predict the prospect of genes using as prognosis factors. RESULTS: After analyzing the microarray data GSE42352, mitosis metaphase to anaphase-related genes CDC20, securin, cyclin A2 and cyclin B2 were found to be overexpressed in osteosarcoma cell lines. Kaplan-Meier survival analysis showed that overexpression of these genes can predict poor prognosis outcomes in osteosarcoma patients. Furthermore, any combination of the four genes seems to be more effective in predicting osteosarcoma outcomes than any of these genes alone. CONCLUSIONS: CDC20 and its downstream substracts securin, cyclin A2 and cyclin B2 are good factors that can predict prognosis outcomes in osteosarcoma. Any two combination of these four genes are more effective to be used as osteosarcoma prognosis factors.
BACKGROUND: We investigated the microarray data GSE42352 to identify genes that can be used as prognosis factors in osteosarcoma. METHODS: Gene Ontology (GO) biological process analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of Cytoscape ClueGo were used in verifying the function of different genes. Realtime-PCR were used to confirm the microarray results. 83 patient samples were collected and underwent Kaplan-Meier survival analysis and multivariate analysis to predict the prospect of genes using as prognosis factors. RESULTS: After analyzing the microarray data GSE42352, mitosis metaphase to anaphase-related genes CDC20, securin, cyclin A2 and cyclin B2 were found to be overexpressed in osteosarcoma cell lines. Kaplan-Meier survival analysis showed that overexpression of these genes can predict poor prognosis outcomes in osteosarcomapatients. Furthermore, any combination of the four genes seems to be more effective in predicting osteosarcoma outcomes than any of these genes alone. CONCLUSIONS:CDC20 and its downstream substracts securin, cyclin A2 and cyclin B2 are good factors that can predict prognosis outcomes in osteosarcoma. Any two combination of these four genes are more effective to be used as osteosarcoma prognosis factors.
Authors: Emilios E Pakos; Andreas D Nearchou; Robert J Grimer; Haris D Koumoullis; Adesegun Abudu; Jos A M Bramer; Lee M Jeys; Alessandro Franchi; Guido Scoccianti; Domenico Campanacci; Rodolfo Capanna; Jorge Aparicio; Marie-Dominique Tabone; Gerold Holzer; Fashid Abdolvahab; Philipp Funovics; Martin Dominkus; Inci Ilhan; Su G Berrak; Ana Patino-Garcia; Luis Sierrasesumaga; Mikel San-Julian; Moira Garraus; Antonio Sergio Petrilli; Reynaldo Jesus Garcia Filho; Carla Renata Pacheco Donato Macedo; Maria Teresa de Seixas Alves; Sven Seiwerth; Rajaram Nagarajan; Timothy P Cripe; John P A Ioannidis Journal: Eur J Cancer Date: 2009-04-06 Impact factor: 9.162
Authors: Marnie Collins; Miriam Wilhelm; Rachel Conyers; Alan Herschtal; Jeremy Whelan; Stefan Bielack; Leo Kager; Thomas Kühne; Matthew Sydes; Hans Gelderblom; Stefano Ferrari; Piero Picci; Sigbjørn Smeland; Mikael Eriksson; Antonio Sérgio Petrilli; Archie Bleyer; David M Thomas Journal: J Clin Oncol Date: 2013-05-13 Impact factor: 44.544
Authors: O Feugeas; N Guriec; A Babin-Boilletot; L Marcellin; P Simon; S Babin; A Thyss; P Hofman; P Terrier; C Kalifa; M Brunat-Mentigny; L M Patricot; F Oberling Journal: J Clin Oncol Date: 1996-02 Impact factor: 44.544
Authors: Marieke L Kuijjer; Elisabeth F P Peterse; Brendy E W M van den Akker; Inge H Briaire-de Bruijn; Massimo Serra; Leonardo A Meza-Zepeda; Ola Myklebost; A Bassim Hassan; Pancras C W Hogendoorn; Anne-Marie Cleton-Jansen Journal: BMC Cancer Date: 2013-05-20 Impact factor: 4.430
Authors: Samantha Bruno; Andrea Ghelli Luserna di Rorà; Roberta Napolitano; Simona Soverini; Giovanni Martinelli; Giorgia Simonetti Journal: J Exp Clin Cancer Res Date: 2022-04-30